Trial Profile

A Randomized Placebo-controlled Trial of Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders (ASD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tideglusib (Primary)
Indications Autism spectrum disorder
Focus Therapeutic Use
Acronyms TIDE

Most Recent Events

06 May 2019 Results presented in an AMO Pharma media release.
06 May 2019 According to an AMO Pharma media release, statistical analysis of results from the study were presented in the treatment of autism spectrum disorder (ASD).
29 Oct 2018 According to AMO Pharma media release, data from this study were presented at at the 65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com